A phase II study of escalated-dose docetaxel with granulocyte colony-stimulating factor support in patients with advanced breast cancer

Abstract

Docetaxel 160 mg/m(2) was delivered with G-CSF support with a very low rate of febrile neutropenia. Non-haematological toxicity was significant, causing five patients to go off study. Effective mobilisation of PBSCs was seen. The response rate of 37.5% was less than that obtained in first-line studies using standard-dose docetaxel 100 mg/m(2), suggesting that there is no additional benefit in dose escalation of this cytotoxic agent in breast cancer patients using this schedule.

The effect of docetaxel on developing oedema in patients with breast cancer: a systematic review

“…Taxane‐containing regimens were subsequently demonstrated to enhance the preventive effects of recurrence compared with the older regimens without taxanes (Mitchell et al . ; Ohsumi et al . ).…”

“…Taxane-containing regimens were subsequently demonstrated to enhance the preventive effects of recurrence compared with the older regimens without taxanes (Mitchell et al 2004;Ohsumi et al 2012). These newer taxane-containing therapies have not yet been evaluated on the magnitude of the risk of developing oedema compared with other therapies.…”